Form 8-K - Current report:
SEC Accession No. 0001654954-20-013839
Filing Date
2020-12-22
Accepted
2020-12-22 16:17:48
Documents
8
Period of Report
2020-12-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vistagen_8k.htm 8-K 53676
2 UNDERWRITING AGREEMENT ex1-1.htm EX-1.1 320503
3 CERTIFICATE OF DESIGNATION OF THE RELATIVE RIGHTS AND PREFERENCES OF THE SERIES ex3-1.htm EX-3.1 91740
4 OPINION OF WOODBURN AND WEDGE. ex5-1.htm EX-5.1 35999
5 PRESS RELEASE ex99-1.htm EX-99.1 14972
6 PRESS RELEASE ex99-2.htm EX-99 15333
7 IMAGE vistagen.jpg GRAPHIC 5699
8 IMAGE ww.jpg GRAPHIC 6331
  Complete submission text file 0001654954-20-013839.txt   550509
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 201408168
SIC: 2834 Pharmaceutical Preparations